ArticleLeukemia2014
Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
Abstract readLetter
In one paragraph
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Trial
- A multigene array for measurable residual disease detection in AML patients undergoing SCT.Bone marrow transplantation · 2015Trial
- Article
- Article
- Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Article
- Review
- AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2020Review
- Immune escape and immunotherapy of acute myeloid leukemia.The Journal of clinical investigation · 2020Review
- Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia.Blood advances · 2020Article
- Article
- Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia.Oncotarget · 2019Article
- The Graft-Versus-Leukemia Effect in AML.Frontiers in oncology · 2019Review
- Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.Frontiers in oncology · 2018Article
- Immunological effects of hypomethylating agents.Expert review of hematology · 2017Review
- Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.Current drug targets · 2017Review
- Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.Current drug targets · 2017Review
- Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.Molecular & cellular proteomics : MCP · 2016Article
- Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).Therapeutic advances in hematology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
M GoswamiMyeloid Malignancies Section, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
N HenselHematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
B D SmithJohns Hopkins University School of Medicine, Baltimore, MD, USA.
G T PrinceJohns Hopkins University School of Medicine, Baltimore, MD, USA.
L QinJohns Hopkins University School of Medicine, Baltimore, MD, USA.
H I Levitsky1] Johns Hopkins University School of Medicine, Baltimore, MD, USA [2] Cancer Immunology Experimental Medicine, Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland.
S A StricklandDivision of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
M JagasiaDivision of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
B N SavaniDivision of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
J W FraserCenter for Leukemia and the Bone Marrow Transplant Unit, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
H SadrzadehCenter for Leukemia and the Bone Marrow Transplant Unit, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
T RajkhowaJohns Hopkins University School of Medicine, Baltimore, MD, USA.
S ItoHematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
N A JainHematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
M BattiwallaHematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
A T FathiCenter for Leukemia and the Bone Marrow Transplant Unit, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
M J LevisJohns Hopkins University School of Medicine, Baltimore, MD, USA.
A J BarrettHematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
C S HouriganMyeloid Malignancies Section, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000000261898067
Funding
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MTUMOR VACCINESP01CA015396 · NCI · JOHNS HOPKINS UNIVERSITY · PI HESS, ALLAN D · 1985 to 2016
$38.1MDetection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0MIntramural NIH HHS ZIA HL006163NCATS NIH HHS UL1 TR001079NCI NIH HHS P01 CA015396
Abstract
PubMed holds no abstract for this paper.
Indexed as
ImmunotherapyHumansLeukemia, Myeloid, Acute
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.